Simvastatin reduces plasma cholesterol by inhibiting HMG-CoA reductase (HMGR) and is widely used in the treatment of hypercholesterolemia. To screening the possible genetic factors affecting the pharmacokinetics (PK) of simvastatin, 35 male Korean volunteers were enrolled from two separate bioequivalence studies. Each subject was administered 20 mg simvastatin and reference drug PK parameters were used. We used Illumina Human610Quad v1.0 DNA Analysis BeadChip for whole genome SNPs analysis and whole genome genotyping data was processed by linear regression analysis for PK parameters of drug metabolizing enzymes and transporters. We found 145 significant SNPs (P < 0.01) in C max , 135 significant SNPs (P < 0.01) in T max and 85 significant SNPs (P < 0.01) in AUC inf from whole genome analysis. In particular, we found that the ABCC2 gene had a significant effect on C max and AUC inf . These results could provide information of possible candidate genes for personalized simvastatin therapy.
Introduction
There is wide interindividual variation in the pharmacokinetics (PK) and pharmacodynamics (PD) of administered drugs, as well as in their effectiveness and the appearance rates of adverse effects. This variation can result from genetic, environmental, physiological, and pathophysiological factors such as age, gender, circadian rhythm, diet, and concomitantly administered drugs and health foods. [1, 2] Single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes are known to be associated with these individual differences. [1] SNPs are unique genetic markers between individuals that contribute in significant ways to the determination of human variation such as personality, behavior and disease susceptibility. SNPs can also significantly influence responses to pharmacotherapy and the production of any adverse drug reactions. [3] SNPs are the most important source of variation in genetic differences [4] and are frequently used as relevant markers of PK. [5] After a common dose, variations in drug efficacy and toxicity can be observed depending on the polymorphisms. [6] The genotyping of drug-metabolizing enzymes prior to drug administration would help to predict individual reactivity to drugs and possible adverse reactions that may occur, which is essential for realizing tailor-made therapy for individual patients. [7] Recent advances in molecular research have revealed that many of the genes that encode drug-metabolizing enzymes demonstrate genetic polymorphisms.
Simvastatin specifically and competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, which is an early rate-limiting step in cholesterol biosynthesis in the body. [8] These agents are highly effective in reducing total cholesterol and low-density lipoprotein levels in several forms of hypercholesterolemia. [9] [10] [11] [12] The purpose of this study is to identify possible candidate genes affecting PK of simvastatin. A total of 35 male Korean volunteers were recruited from two bioequivalence studies after approval by the Institutional Review Board (IRB) of Kyung Hee University Hospital. In this study, DNA from each subject was analyzed using Illumina Human610Quad v1.0 DNA Analysis BeadChip. Linear regression analysis was performed for significant SNPs against the PK parameters, such as maximum measured plasma concentration (C max ), time of the maximum measured plasma concentration (T max ) and area under the plasma concentration-time curve from zero to infinity (AUC inf ) [13] from drug metabolizing enzymes and transporters.
Previous bioequivalence studies
Previous studies were based on two simvastatin bioequivalence tests. Each bioequivalence study of two 20 mg simvastatin formulations (reference drug, Zocor 20 mg, MSD Co., Ltd., Seoul, Korea) was conducted in healthy male Korean volunteers after a single dose administration in a randomized cross-over study with a washout period of at least one week. The subjects were hospitalized (Kyung Hee University Hospital, Seoul, Korea) and fasted overnight (10 h) and until 4 h after each drug administration. The doses were administered at 8.00 a.m. of each dosing day along with 240 ml of tap water. No food was allowed until 4 h after dose administration. Approximately 7 ml of blood for simvastatin and active metabolite assays were drawn into heparinized tubes through indwelling cannula before (0 h) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 36 h after dosing. Blood samples were centrifuged at 3000 rpm for 10 min; plasma was separated and kept frozen at -70°C until assayed. Plasma was analyzed for simvastatin concentration using a validated highperformance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
Pharmacokinetics analysis
PK parameters (C max , T max , AUC t and AUC inf ) were calculated by noncompartmental models in WinNonlin v5.2 (Table 1) .
DNA extraction
From November 2008 to January 2009, blood samples were obtained from 35 participants. After obtaining informed consent, approximately 10 ml of whole blood was collected from each participant. Blood samples were drawn into sterile tubes containing ethylenediaminetetraacetic acid (EDTA) and stored at -70°C until the isolation of genomic DNA. Genomic DNA was isolated from the blood sample by a standard phenol chloroform extraction method.
Genotyping
SNPs of 35 healthy male volunteers were analyzed by Standard Illumina procedures using Illumina BeadStation 500G (Illumina Human610Quad v1.0 DNA Analysis BeadChip) according to the Illumina manual (Illumina, San Diego, CA, USA). Intensity files (*.idat) were processed by BeadStudio GT module 3.3.4 with default analysis settings. Each SNP was analyzed independently to cluster and identify genotypes. Genotype calls were generated by comparing experimental data with those in the supplied cluster file (*.egt). The SNP set was filtered on the basis of genotype call rates (≥ 95%), and minor allele frequency (MAF ≥ 0.05).
Statistical analysis & data analysis
Hardy Weinberg equilibrium (HWE) was calculated for individual SNPs using an exact test. All of the SNPs reported in this manuscript have HWE P-values > 0.001. To calculate the degree (Beta), 95% confidence intervals (CI) and P-value while controlling for age, height and weight as covariants in a linear regression analysis with significant SNPs on individual PK parameters of simvastatin, unadjusted genotypic association with additive, dominant and recessive models were tested by calculating the Beta and P-value using PLINK version 1.06 (Shaun Purcell, USA). When the additive model was used, each genotype was independently coded as 0, 1, or 2 and analyzed. In the dominant model, a homozygote major allele and another two genotypes were coded as 0 and 1 and analyzed. In the recessive model, a homozygote minor allele and another two genotypes were coded a 0 and 1 and analyzed. After filtering, SNPs were analyzed on chromosome 1 through chromosome 22 for each group.
Significant SNPs were identified from each PK parameter (C max , T max and AUC inf ). Among these, SNPs of phase I and II enzymes, transporters and non-cytochrome metabolic enzymes were selected from the DMET Plus Marker List in Additional Support, DMET TM (Drug-Metabolizing Enzymes and Transporters), Affymetrix, Inc (AFFX) (http://www.affymetrix.com/products_ services/arrays/specific/dmet.affx#1_4).
Results

Pharmacokinetics analysis
The PK parameters of simvastatin are shown in Table 1 . C max is 7.5 ± 4.8 ng/ml, T max is 1.9 ± 1.2 h, AUC t is 29.7 ± 16.8 ng·h/ ml and AUC inf is 34.8 ± 20.0 ng·h/ml. These data were used for linear regression analysis.
SNPs analysis
PK parameters of C max , T max and AUC inf were analyzed by linear regression analysis. For clinical pharmacological purposes, significant genes encoding phase I and II enzymes, transporters and noncytochrome metabolic enzymes were selected for further analysis. These analyses were adjusted for age, height
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Transl Clin Pharmacol and weight. We found 145 possible candidate SNPs (P < 0.01) including 7 highly s possible candidate SNPs (P < 0.00001) in C max , 135 possible candidate SNPs (P < 0.01) including 2 highly possible candidate SNPs (P < 0.00001) in T max , and 85 possible candidate SNPs (P < 0.01) including 3 highly possible candidate SNPs (P < 0.0001) in AUC inf from whole genome analysis (Table  2 ). In the C max group, we found several highly possible candidate SNPs among drug-metabolizing enzymes and transporters ( Table 3 ). For example, SLC44A3 (rs696620) showed statistically significant changes by genotype in a recessive model (P = 2.580x10 -4 ). SLC4A5 (rs10182348, rs10211612, rs2421844, rs3755441, rs3771740, rs3821303, rs7567768, rs7592599 and rs9789404) showed statistically possible changes by genotype with LD blocks in a recessive model (P = 1.604x10 -4 ). SLC2A12 (rs2811675) showed statistically possible changes by genotype in additive, dominant and recessive models (P = 3.621x10 -4 ; P = 0.006; P = 0.003, respectively). Other possible candidateSNPs are presented in Table 3 . Also, SNPs of simvastatin PK pathways in the C max group were analyzed. Certain SNPs, such as CYP3A5, ABCC2 and SLCO1B3, showed statistically possible changes by genotype (Supplementary table 1 ).
In the T max group, we found several highly possible candidateSNPs among drug-metabolizing enzymes and transporters (Table 4) . For example, ABCC4 (rs1059751, rs3742106, rs4148549, rs4148553 and rs7330196) showed statistically possible changes by genotype with LD blocks in additive and recessive models (P = 0.001; P = 9.468x10-4, respectively). CYP2F1 (rs305968) showed statistically possible changes by genotype in additive, dominant and recessive models (P = 5.876x10 -4 ; P = 5.239x10 -4 ; P = 0.032, respectively). Other possible candidate SNPs are presented in Table 4 . Also, SNPs of simvastatin PK pathways in the T max group were analyzed. Certain SNPs, such as UGT2B7 and ABCG2, showed statistically possible changes by genotype (Supplementary table 2 ). In the AUC inf group, we found several highly possible candidate SNPs among drug-metabolizing enzymes and transporters (Table 5). For example, SLC2A12 (rs2811675) showed statistically possible changes by genotype in additive and dominant models (P = 0.002; P = 0.001, respectively). SLC18A1 (rs4922132) showed statistically possible changes by genotype in additive, dominant and recessive models (P = 3.414x10 -4 ; P = 0.004; P = 0.010, respectively). Other significant SNPs are presented in Table 5 . Also, SNPs of simvastatin PK pathways in AUC inf group were analyzed. Certain SNPs, such as ABCC2, showed statistically possible changes by genotype (Supplementary table 3) .
Although minor genotypes showed very low frequencies in some SNPs, their effects on PK parameters were great. For example, two volunteers who had the GG genotype of rs11183395 (SLC38A1) and the TT genotype of rs10483482 (SLC25A21) exhibited two-fold increases in C max (Table  3 ). In the T max group, two volunteers who had the CC genotype of rs4646715 (ALDH1L1) showed delayed absorption of simvastatin, while nine volunteers who had the AA genotype of rs305968 (CYP2F1) showed accelerated absorption of simvastatin (Table 4) . Also, in the AUC inf group, two volunteers who had the GG genotype of rs7830129 (SLC25A37) exhibited two-fold increases in simvastatin absorption (Table 5) . These results suggest that genotype can affect simvastatin PK.
Discussion
Simvastatin is widely used in the treatment of hypercholesterolemia. It reduces low density lipoprotein (LDL) cholesterol concentrations by inhibiting cholesterol synthesis in the liver. [14] Many clinical trials have shown that simvastatin reduces the risk of death and other complications in patients with chronic heart disease. [15] [16] [17] Recently, many studies have reported a relationship between genetic polymorphisms and simvastatin PK. [18] [19] [20] [21] However, there has been no study concerning PK of simvastatin and whole genome SNPs analysis. In this study, we conducted a whole genome SNPs analysis to investigate possible candidate genes for simvastatin PK. We analyzed three PK parameters (C max , T max and AUC inf ). For clinical pharmacological purposes, candidate genes which showed statistically possible differences among phase I and II enzymes, transporters and non-cytochrome metabolic enzymes were selected for further analysis. These analyses were adjusted for age, height and weight. Several SNPs showed possible differences in each group by linear regression analysis. Among the significant SNPs, although their minor allele frequency was relatively very small (n = 2 to 4), some SNPs showed great changes in PK parameters. These results are closely related with rare extensive or poor metabolizers in drug metabolism. For example, the CYP3A5 genotype is related to genetic variation in the pharmacokinetics of tacrolimus, and CYP3A5 genotype (*1/*1, *1/*3, *3/*3) is related to levels of tacrolimus in living-donor liver transplant recipients. The trough blood levels (C 0 ) of tacrolimus were substantially lower in patients receiving livers with CYP3A5*1/*3 genotype (CYP3A5 non-expressers) than CYP3A5*3/*3 genotype (CYP3A5 expressers), which may hinder a stronger effect of the donor's genotype on tacrolimus dose requirements. [22] Based on the current study, genetic polymorphisms, especially SNPs, could have effects on simvastatin concentration and PK parameters. In the AUC inf group (Table 5) , ARNT and five SLC transporters including SLC45A2 showed statistically strong differences (P < 0.001). The aryl hydrocarbon receptor nuclear translocator (ARNT) is a member of the basic helix-loop-helix/ PERARNT-SIM (bHLH/PAS) family of proteins. [23] In this study, minor allele homozygotes (G) of rs2134688 of ARNT might be associated (P = 3.188x10 -4 , in recessive model; Table  5 ) with increased absorption of simvastatin. The SLC45A2 gene, which encodes a transporter protein involved in melanin synthesis, is considered one of the most important genes affecting human pigmentation. [24] Our results showed that minor allele homozygotes (A) of rs35390 of SLC45A2 might beassociated (P = 0.007 and P = 8.877x10 -5 , in additive and recessive models, respectively; Table 5 ) with an increased absorption of simvastatin. SLC25A37 (Mitoferrin-1; Mfrn1), a member of the solute carrier family localized in the mitochondrial inner membrane, functions as an essential iron importer for the synthesis of mitochondrial heme and iron-sulfur clusters in erythroblasts. [25] There have been no studies about genetic polymorphisms of SLC25A37 to date. In this study, minor allele homozygotes (G) of rs7830129 of SLC25A37 might be associated (P = 4.141x10 -4 , in recessive model; Table 5 ) with increased absorption of simvastatin. We suggest that the results of this study could be used for further study to predict simvastatin PK parameters.
In the C max group (Table 3) , ALDH3B1, ABCC4 transporter, and five SLC transporters including SLC44A3 showed statistically strong differences (P-value < 0.001). Recent studies have linked SNPs at the ALDH3B1 locus to the development of paranoid schizophrenia. [26] [27] [28] In this study, major allele homozygotes (G) of rs2286168 of ALDH3B1 might be associated (P = 4.120x10 -4 and P = 9.759x10 -6 , in additive and dominant models, respectively; Table 3 ) with decreased absorption of simvastatin. ABCC4 encodes MRP4, a member of the ATP-binding cassette family of membrane transporters involved in the efflux of endogenous and xenobiotic molecules. [29] Although ABCC4 is a highly polymorphic gene, [30] Table 3 . continued Abbreviation; Chr: chromosome, n: number, SD: standard deviation, CI: confidence intervals, LCL: lower confidence limit, UCL: upper confidence limit, Sig: significant. *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Screening study for pharmacogenomics of simvastatin Table 4 . continued Abbreviation; Chr: chromosome, n: number, SD: standard deviation, CI: confidence intervals, LCL: lower confidence limit, UCL: upper confidence limit, Sig: significant. *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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was associated with a trend toward elevated AZT-triphosphate, suggesting reduced MRP4 efflux function. [31] Interestingly, the 4131T>G variant is in the 3'-untranslated region (UTR) of the gene, while the 3724G>A variant is synonymous; there is therefore no clear mechanism explaining these effects. In another study, no association was observed between two non-synonymous and seven synonymous ABCC4 variants and tenofovir disoproxil fumarate-induced renal proximal tubulopathy. [32] Most recently, 74 genetic variants in ABCC4 were shown to have no effect on MRP4 mRNA and protein expression in Caucasian cholestatic and non-cholestatic patients. [33] However, they reported that ABCC4 genotype affected drug metabolism. In this study, minor allele homozygotes (C) of rs4148436 of ABCC4 were significantly associated (P = 2.941 x10 -4 , P = 0.008 and P = 8.436x10 -4 , in additive, dominant and recessive models, respectively; Table 3 ) with increased absorption of simvastatin. Based on these results, we suggest that these genes could be used for candidate genes for prediction of simvastatin pharmacogenomics study.
In the T max group (Table 4) , ALDH1L1, CYP2F1, ABCA4, ABCC4, and four SLC transporters including SLC39A11 showed statistically strong differences (P < 0.001). Minor allele homozygotes (A) of rs305968 of CYP2F1 might be associated (P = 5.786x10 -4 , P = 5.239x10 -4 and P = 0.032 in additive, dominant and recessive models, respectively; Table 4 ) with accelerated absorption of simvastatin. Also, minor allele homozygotes (C) of rs1059751 of ABCC4 might be associated (P = 0.001 and P = 9.468x10 -4 in additive and recessive models, respectively; Table  4 ) with delayed absorption of simvastatin. By linear regression analysis, the ABCC4 gene has a strong effect on C max and T max , together. We also found several significant SNPs affecting simvastatin PK pathways using whole-genome linear regression analysis. In the C max group, CYP3A5, three ABC transporters including ABCB11, and two SLC transporters including SLCO2B1 showed relatively weak differences (P < 0.05). Minor allele homozygotes (C) of rs10208831 of ABCB11 might be associated (P = 0.004, P = 0.013 and P = 0.025, in additive, dominant and recessive models, respectively) with increased absorption of simvastatin (Supplementary Table 1 ). In the T max group, UGT2B7, three ABC transporters including ABCG2, and three SLC transporters including SLCO1B1 showed relatively weak differences (P < 0.05). Major allele homozygotes (C) of rs10028494 of UGT2B7 might be associated (P = 0.013 in recessive model) with increased absorption of simvastatin. Our results suggest that UGT2B7 could have a clinically important effect on simvastatin absorption (Supplementary Table 2 ). Major allele homozygotes (T) of rs2306283 of SLCO1B1 might be associated (P = 0.007, P = 0.024 and P = 0.036 in additive, dominant and recessive models, respectively) with accelerated absorption of simvastatin. Hence, polymorphisms of SLCO1B1 gene could be assessed in order to tailor simvastatin treatment (Supplemnetary Table 3 ). In the AUC inf group, ABCC2 and SLC15A1 showed relatively weak differences (P < 0.05). Minor allele homozygotes (C) of rs3740065 of ABCC2 might be associated (P = 0.005 in recessive model) with increased absorption of simvastatin. ABCC2, the gene encoding MRP2, is expressed on the bile canalicular membrane and plays an important role in the biliary excretion of various substrates. [34] Genetic variations in the ABCC2 gene have been reported to alter functional activity, thereby contributing to interindividual differences in drug disposition. [35] The ABCC2 gene is also involved in the inhibition of biliary excretion HMGR. [34, 36, 37] By whole genome linear regression analysis, we found several highly possible candidate SNPs which affecting PK parameters of simvastatin. Interestingly, except for few SNPs of phase I and phase II enzymes, such as CYP3A5 (C max ) (Supplemnetary Table  1 ) and CYP2F1 (T max ), most of the significant SNPs were found in transporters. Previous studies have been performed on drugmetabolizing enzymes, but our results showed that transporters can have great influences on the PK of drugs in PK study. For example from this study, we found that the ABCC2 gene could be a candidate gene for personalized simvastatin therapy. The ABCC2 gene has a strong effect on C max and AUC inf , together. Other SNPs also can be candidate biomarkers for clinical use in tailored simvastatin administration.
In this study, we performed linear regression analysis for PK parameters of simvastatin. The screened SNPs from this study might be related to the PK of simvastatin and used for tailored pharmacotherapy of simvastatin. But our study has significant limitations. Because of small sample size, Bonferroni correction cannot be adjusted. Although we have no SNPs which can be used for prediction of simvastatin pharmacogenomics because all significant SNPs showed p value above 10 -6 , SNPs from this study could be used for candidate genes for further study. So further studies for simvastatin pharmacogenomics using SNPs from this study are needed.
